2 July 2024
Researchers of Biogipuzkoa HRI lead a study that relates the use of antipsychotics in dementia with socioeconomic status
Disparities by socioeconomic status have been noted in the use of antipsychotics both in the general population and in people with dementia. An analysis of 221,777 individuals over 60 years of age has revealed the greater likelihood of receiving antipsychotics among people with low socioeconomic status. Increasing the offer of non-pharmacological treatments might help reduce inequity in antipsychotic use.
12 June 2024
Omics Research and AI Tools Are Contributing to Our Understanding of What Causes Alzheimer’s Disease
With the advent of new omics technologies in recent years, there has been a deluge of complex, high-dimensional data on Alzheimer’s disease (AD). A topical collection of articles on omics approaches in AD research in a supplement to the Journal of Alzheimer’s Disease (JAD), published by IOS Press, provides new insights into altered pathways and disease-related processes, increasing our understanding of AD pathogenesis to identify specific biomarkers of disease status, progression, and therapeutic response.
23 May 2024
New Group Training Tool for the Prevention of Dementia
Solving a quiz as a group while moving around the room at the same time – this combination is the basis of a new tool designed to prevent dementia. Researchers developed and evaluated it in the “go4cognition” project with industry partners and brought it to market maturity. Vanessa Lissek and Professor Boris Suchan from Ruhr University Bochum, Germany, and Stefan Orth from the company Ontaris describe how effective the training with the system is in the Journal of Alzheimer Disease.
21 May 2024
Does Managing Oxidative Stress Hold the Key to Effectively Treating Alzheimer’s Disease
The number of people suffering from Alzheimer’s disease (AD) is expected to reach 100 million by 2050, but there is still no effective therapy. Leading researchers from around the world assess how oxidative stress (OS) may trigger AD and consider potential therapeutic targets and neuroprotective drugs to manage the disease in a collection of articles in a special supplement to the Journal of Alzheimer’s Disease, published by IOS Press.
8 May 2024
Considering Many Factors Causing Older Veteran’s Cognitive Difficulties May Improve Personalized Care
A new study investigated how measures of thinking, memory, and Alzheimer’s disease risk group together in Veterans aged 65 and older without dementia. Results of the study showed multiple patterns of cognitive strengths and weaknesses and Alzheimer’s disease risk and may imply that older Veterans with certain cognitive difficulties could mistakenly receive a diagnosis of possible Alzheimer’s disease, when other factors such as PTSD may really be the root cause of the cognitive difficulties.
5 April 2024
UM Researcher writes about a key issue for the US 2024 elections: Air pollution exposures ought to be of significant interest for US voters
An opinion paper published by University of Montana professor Lilian Calderón-Garcidueñas MD, PhD identifies air pollution risk exposures and the development of Alzheimer’s and Parkinson’s diseases, frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) in exposed populations.
22 March 2024
Dementia care research recognised internationally
Uniting NSW.ACT and UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) teamed up to co-author a research paper about the impact of person-centred intervention on the quality of healthcare and clinical outcomes for people living with dementia at Uniting’s War Memorial Hospital with successful results – winning praise, and publication, from the Journal of Alzheimer’s Disease. The research paper concluded the person-centred care model significantly improved clinical outcomes for people living with dementia, after hospitilisation.
22 March 2024
Researchers identify a mutation that alters Alzheimer's disease progression
The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary specialists, identifying a mutation that alters Alzheimer's disease progression. This work, published in the Journal of Alzheimer’s Disease, has characterized a genetic variant in SIRPβ1 gene, which affects the way in which the immune system fights against beta-amyloid deposits, the cause that leads to this pathology.
15 March 2024
Cleveland Clinic-Led Research Supports Repurposing Sildenafil (Viagra) For Alzheimer’s Treatment
New Cleveland Clinic-led research points to sildenafil (Viagra) as a potential treatment for Alzheimer’s disease. The study provides evidence from computational models, insurance claims data and observations from brain cells in Alzheimer’s patients.
29 February 2024
Unlocking Alzheimer’s secrets
Medical University of South Carolina researchers report in the Journal of Alzheimer’s Disease that worsened anxiety, depression and other neuropsychiatric symptoms predict progression from mild cognitive impairment to full-blown Alzheimer's disease. People with MCI may struggle with thinking and remembering more than their peers but can still carry out everyday tasks, unlike those with AD. These findings highlight the importance of NPS in improving early detection and refining models to predict the progression of AD.
Pages
